TrialSafety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Trial details
- Registry ID
- NCT04091646
- Phase
- Phase 2
Drug research
Roflumilast Foam 0.3%
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as ARQ-154; ARQ-154 0.3%
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic DermatitisNCT04091646 | ARQT | Phase 2 | Completed | 2020-08-18Actual |
| Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)NCT05028582 | ARQT | Phase 3 | Completed | 2022-06-03Actual |
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
Trial details
- Registry ID
- NCT05028582
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |